<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162952">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675596</url>
  </required_header>
  <id_info>
    <org_study_id>2011-14</org_study_id>
    <nct_id>NCT01675596</nct_id>
  </id_info>
  <brief_title>The SOLACE-AU Clinical Trial</brief_title>
  <acronym>SOLACE-AU</acronym>
  <official_title>A Multicentre, Non-Randomised Controlled Study of the Safety, Performance, Quality of Life and Cost Effectiveness Outcomes of the Edwards SAPIEN XT™ Transcatheter Heart Valve in an Australian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacific Clinical Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to observe the safety, efficacy and cost effectiveness of the
      Edwards SAPIEN XT valve for the treatment of severe calcific degenerative aortic stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-centre, prospective, consecutively enrolled, non-randomised controlled clinical trial.
      The comparatator group will consist of sub-jects undergoing surgical aortic valve
      replacement in Cohort A of the PARTNER II Trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>VARC Composite Safety Endpoint</measure>
    <time_frame>30 days post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>(comprising of the following VARC Composite Safety Endpoints)
All cause mortality
Major stroke
Life-threatening (or disabling) bleeding
Acute kidney injury - Stage 3 (including renal replacement therapy)
Peri-procedural MI
Major vascular complications
Repeat procedure for valve-related dysfunction (surgical or interventional therapy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>At 6 and 12 months post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cardiovascular mortality (VARC definition) at 30 days, 6 months and 12 months post index procedure
Stroke (VARC definition) at 30 days, 6 months and 12 months post index procedure
Vascular complications (VARC definition) at 30 days post index procedure
Acute kidney injury (VARC definition)
New York Heart association (NYHA) Functional Status at 30 days, 6 months and 12 months post index procedure
Device Success
Quality of Life assessments at 30 days, 6 months, 1, 2, 3, 4, and 5 years post index procedure
Number of admissions and total days in hospital at 12 months post index procedure
Health care costs at 12 months post index procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Severe, Symptomatic Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAPIEN XT™ valve with the NovaFlex delivery system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVR Implantation of the Transcatheter Aortic Valve Prosthesis</intervention_name>
    <description>Operable subjects</description>
    <arm_group_label>Test</arm_group_label>
    <other_name>Implantation of the Transcatheter Aortic Valve Prosthesis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Age &gt; 70 AND STS Score &gt; 4

               -  Heart team agrees on eligibility including assessment that TAVR or AVR is
                  appropriate

               -  Heart team agrees (a priori) on treatment strategy for concomitant coronary
                  disease (if present)

               -  Patient has senile degenerative aortic valve stenosis with
                  echocardio-graphically derived criteria

               -  Symptomatic aortic valve stenosis, as demonstrated by NYHA Functional Class II
                  or greater

               -  The heart team agrees  that valve implantation will likely benefit the patient

               -  The study patient or the study patient's legal representative agrees to written
                  informed consent as approved by the HREC of the respective clinical site

               -  The study patient agrees to comply with all required post-procedure follow-up
                  visits

        Exclusion Criteria:

          -  • Heart  Team assessment of inoperability, Age  &lt;70years, Evidence of an acute
             myocardial infarction ≤ 30 days,

               -  Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is
                  non-calcified,

               -  Mixed aortic valve disease,

               -  Preexisting bioprosthetic valve in any position,

               -  Unprotected left main coronary artery stenosis considered functionally
                  sig-nificant,

               -  Any therapeutic invasive cardiac procedure resulting in a permanent implant,

               -  Any patient with a BAV within 30 days of the procedure,

               -  Leukopaenia, acute anaemia, Thrombocytopaenia,

               -  Hypertrophic cardiomyopathy with or without obstruction,

               -  Severe ventricular dysfunction with LVEF &lt; 20%,

               -  Echocardiographic evidence of intracardiac mass,

               -  Active upper GI bleeding within 90 days prior to procedure,

               -  A known contraindication or hypersensitivity to all anticoagulation regimens,

               -  Native aortic annulus size &lt; 18mm or &gt; 25mm as measured by echocardio-gram,

               -  Clinically (by neurologist) confirmed stroke or TIA within 180 days of the
                  procedure

               -  Renal insufficiency,

               -  Estimated life expectancy &lt; 365 days,

               -  Expectation that patient will not improve despite treatment of aortic stenosis,

               -  Significant aortic disease,

               -  Iliofemoral vessel characteristics that would preclude safe placement of 18F or
                  19F introducer sheath,

               -  Currently participating in an investigational drug or another device study,

               -  Active bacterial endocarditis or within 6 months (180 days) of procedure.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren Walters, A/Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Prince Charles Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Graham</last_name>
    <phone>+61 488 075 474</phone>
    <email>scott_graham@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meryl Musson</last_name>
    <phone>+61 2 8811 2604</phone>
    <email>meryl_musson@edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Ng, Dr.</last_name>
      <phone>+61 2 9515 7609</phone>
      <email>mkcng@med.usyd.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Janan Fornusek</last_name>
      <phone>+61 2 9591 7885</phone>
      <email>Janan.fornusek@sswahs.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Ng, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Macquarie Unversity Hospital</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Ng</last_name>
      <phone>+61 2 9515 7609</phone>
      <email>mkcng@med.usyd.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Josie Gabrielli</last_name>
      <phone>+61 2 9812 3845</phone>
      <email>Josie.gabrielli@muh.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Ng, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwich</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nigel Jepson, Dr.</last_name>
      <phone>+61 2 9382 0762</phone>
      <email>Nigel.jepson@ehc.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Anne Russell</last_name>
      <phone>+61 2 9382 0489</phone>
      <email>Anne.russell@sesiahs.health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Nigel Jepson, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Bhindi, Dr.</last_name>
      <phone>+61 416 005 737</phone>
      <email>rbhindi@med.usyd.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Annie Loxton</last_name>
      <phone>+61 2 9463 2520</phone>
      <email>Annie.loxton@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Ravi Bhindi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren Walters, Assoc Prof</last_name>
      <phone>+61 7 3139 4710</phone>
      <email>Darren_Walters@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Helen Nahuysen</last_name>
      <phone>+61 7 3139 4711</phone>
      <email>Helen_Nahuysen@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Darren Walters, Assoc Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Professor Stephen Worthley, Professor</last_name>
      <phone>+61 8 8222 2890</phone>
      <email>stephen.worthley@health.sa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Roach</last_name>
      <phone>+61 8 8222 2889</phone>
      <email>Ashley.roach@health.sa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Professor Stephen Worthley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay Sinhal</last_name>
      <phone>+61 8 8204 5000</phone>
      <email>ajay.sinhal@sahmri.com</email>
    </contact>
    <contact_backup>
      <last_name>Frances Kissajukian</last_name>
      <phone>+61 8 8204 4440</phone>
      <email>frances.kissajukian@sahmri.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ajay Sinhal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Walton</last_name>
      <phone>+61-3-9426 6693</phone>
      <email>twalton93@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Holland</last_name>
      <phone>+61 3 9076 3269</phone>
      <email>S.Holland@alfred.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Tony Walton, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital - MELBOURNE</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rob Whitbourn, Dr</last_name>
      <phone>+61 3 9288 4440</phone>
      <email>Robert.whitbourn@svhm.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Peeler</last_name>
      <phone>+61 3 9288 4442</phone>
      <email>Catherine.peeler@svhm.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Rob Whitbourn, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronen Gurvitch, Ddr.</last_name>
      <phone>+61 412 878 600</phone>
      <email>Ronen.gurvitch@yahoo.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Ogden</last_name>
      <phone>+61 9342 7434</phone>
      <email>Vanessa.ogden@mh.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Ronen Gurvitch, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Yong, Dr.</last_name>
      <phone>+61 8 9224 2086</phone>
      <email>gstyong@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Diana Khoo</last_name>
      <phone>+61 8 9924 3837</phone>
      <email>Diana.khoo@health.wa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Yong, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 9, 2013</lastchanged_date>
  <firstreceived_date>August 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Transfemoral</keyword>
  <keyword>Transcatheter Heart Valve</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
